The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: A systematic review and value of information analysis

Health Technology Assessment

Volumn 13, Issue 31, 2009, Pages

  Rogowski, W ^a   Burch, J ^b   Palmer, S ^c   Craigs, C ^b   Golder, S ^b   Woolacott, N ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTERY DISEASE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; HEALTH CARE COST; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; NON ST ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT ELEVATION; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; DRUG COMBINATION; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED KINGDOM; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 68249102577     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta13310     Document Type: Review

References (122)

1. Grech ED, Rainsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ 2003;326:1259-1261
2. Bennett MJ. Acute coronary syndrome and cardiogenic shock. Anaesth Intensive Cure Med 2004;2:421-424
3. Petersen S, Peto V, Rayner M. Coronary heart disease statistics. London: British Heart Foundation; 2004.
4. Primatesta P. Health survey for England 2003: volume 1 Cardiovascular disease. London: The Stationery Office; 2004.
5. Department of Health. Coronary heart disease: national service framework for coronary heart disease - modern standards and service models [online]. Department of Health; 2000. Available from: www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-4094275 (accessed 10 September 2007).
6. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. JAMA 1988;260:2088-2093
7. Fox KAA. Management of acute coronary syndromes: an update. Heart 2004;90:698-706. (Pubitemid 38668556)
8. Rosengren A, Wilhelmsen L, Hagman M, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden. J Intern Med 1998;244:495-505. (Pubitemid 28552856)
9. Fitchett D, Goodman S, Langer A. New advances in the management of acute coronary syndromes: 1. Matching treatment to risk. CMAJ 2001;164:1309-16.
10. Prescription Pricing Authority. PACT centre pages - primary prevention of cardiovascular disease. NHS Business Services Authority; 2005. Available from: www.nhsbsa.nhs.uk/PrescriptionScrvices/Documents/PPDImpact/imPACT-June-2005.pdf (accessed 18 May 2009).
11. Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597-603. (Pubitemid 35418074)
12. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004;8(40). (Pubitemid 39585965)
13. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
14. Jacobson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol 2004;17:55-64.
15. Watson RDS, Chin BSP, Lip GYH. ABC of antithrombotic therapy: antithrombotic therapy in acute coronary syndromes. BMJ 2002;325:1348-1351 (Pubitemid 35471558)
16. NICE. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. (Technology appraisal guidance; no. 80). London: National Institute for Health and Clinical Excellence; 2004.
17. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687 (Pubitemid 37243654)
18. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972 (Pubitemid 36258718)
19. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622-1626
20. Morais J. Insights from CURE: using clopidogrel on top of standard therapy. Cerebrovasc Dis 2002;13(Suppl 1):17-21. (Pubitemid 34102523)
21. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
22. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14:312-318 (Pubitemid 46650089)
23. MedlinePlus®: medical dictionary [online]. US National Library of Medicine. Available from: www.nlm.nih.gov/medlineplus/mplusdictionary.html (accessed 23 October 2007).
24. Anxiety Disorders Association of America: glossary [online]. Anxiety Disorders Association of America. Available from: www.adaa.org/gettinghelp/ glossary.asp (accessed 23 October 2007).
25. eMedicineHealth [online]. WebMD, Inc. Available from: www.emedicinehealth.com (accessed 23 October 2007).
26. Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104:2772-2777 (Pubitemid 33126649)
27. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients [letter]. Int J Cardiol 2000;76:257-258 (Pubitemid 30947017)
28. Bachman DS. Discontinuing chronic aspirin therapy: another risk factor for stroke? [letter]. Ann Neurol 2002;51:137-138
29. Beving H, Zhao C, Albåge A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996;7:80-84 (Pubitemid 26106173)
30. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005;62:1217-20. (Pubitemid 41168347)
31. Albaladejo P, Geeraerts T, Francis F, Castier Y, Lesèche G, Marty J. Aspirin withdrawal and acute lower limb ischemia. Anesth Analg 2004;99:440-443 (Pubitemid 38970416)
32. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-2674 (Pubitemid 44729867)
33. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935
34. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Büller HR, Levi M, et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811-817 (Pubitemid 34185328)
35. Bijsterveld NR, Peters RJ, Murphy SA, Bernink PJ, Tijssen JG, Cohen M. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 2003;42:2083-2089 (Pubitemid 37549889)
36. Watkins MW, Luetmer PA, Schneider DJ, Witmer WT, Vaitkus PT, Sobel BE. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. Cathet Cardiovasc Diagn 1998;44:257-264
37. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med 2006;119:e11-16.
38. Ho MP, Peterson EE, Wang L, Magid DJ, Film SD, Larsen GC, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-539 (Pubitemid 351222546)
39. Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006;28:860-871 (Pubitemid 44081951)
40. Pekdemir H, Cin VG, Camsari A, Cicek D, Akkus MN, Doven O, et al. A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation. Heart Vessels 2003;18:123-129 (Pubitemid 36974965)
41. Akbulut M, Ozbay Y, Karaca I, Ilkay E, Gundogdu O, Arslan N. The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coron Artery Dis 2004;15:347-352 (Pubitemid 39302658)
42. Bernardi V, Szarfer J, Summay G, Mendiz O, Sarmiento R, Alemparte MR, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007;99:349-352 (Pubitemid 46149552)
43. Steinhubl SR, Berger PB, Mann JT, Fry EFA, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420 (Pubitemid 35340537)
44. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-924 (Pubitemid 37048218)
45. Slawson D. What is the optimal duration of combination aspirin and clopidogrel therapy after percutaneous coronary intervention? Evid Based Pract 2003;6:6.
46. Tang WHW, Steinhubl SR, Van Lente F, Brennan D, McErlean E, Maroo A, et al. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J 2007;153:36-41. (Pubitemid 44880884)
47. Averkov OV, Slavina NN, Gratsianski NA. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel] [Russian]. Kardiologiia 2003;43:50-59
48. Slavina NN, Averkov OV, Dobrovol'ski AB, Gratsianski NA. [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel] [Russian]. Kardiologiia 2003;43:4-11.
49. Slavina NN, Averkov OV, Gratsianski NA. [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome] [Russian]. Kardiologiia 2005;45:11-16.
50. Mueller C, Roskamm H, Neumann FJ, Hunziker P, Marsch S, Perruchoud A, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 2003;41:969-973 (Pubitemid 36315539)
51. Juergens CP, Wong AM, Leung DY, Lowe HC, Lo S, Fernandes C, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation. Am Heart J 2004;147:K1-K5. (Pubitemid 38900457)
52. Biondi-Zoccai GGL, Agostoni P, Sangiorgi GM, Iakovou I, Antoniucci D, Grube E, et al. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) study. Int J Cardiol 2006;108:406-407 (Pubitemid 43339814)
53. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629 (Pubitemid 30640661)
54. Berger PB, Bell MR, Rihal CS, Ting H, Barsness G, Garratt K, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891-1901 (Pubitemid 30002640)
55. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents. JAMA 2005;293:2126-2130 (Pubitemid 40617065)
56. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780-784
57. Pfisterer M, Brunner-La Rocca HP, Buser IT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus baremetal stents. J Am Coll Cardiol 2006;48:2584-2591 (Pubitemid 44881238)
58. Han Y-L, Wang S-L, Jing Q-M, Yu H-B, Wang B, Ma Y-Y, et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin Med J 2007;120:552-556 (Pubitemid 46629908)
59. Rau M, Maikowski C, Weber M, Keil E, Elsasser A, Mollmann H, et al. [Treatment of in-stent restenosis with sirolimus-eluting-stents - a six month clinical and angiographic follow-up] [German]. Z Kardiol 2005;94:742-747
60. Carlsson J, von Wagenheim B, Linder R, Anwari TM, Qvist J, Petersson I, et al. Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin Res Cardiol 2007;96:86-93. (Pubitemid 46233210)
61. Balaguer-Malfagon JR, Pomar-Domingo F, Vilar-Herrero JV, Planas-del Viejo AM, Perez-Fernandez E. [Stent thrombosis in the modern era: Incidence, outcome and predictive factors] [Spanish]. Rev Esp Cardiol 2006;59:842-845
62. Picker SM, Kaleta T, Hekmat K, Kampe S, Gathof BS. Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome. Eur J Anaesthesiol 2007;24:332-339 (Pubitemid 46270967)
63. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999;99:248-253 (Pubitemid 29056367)
64. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-2809
65. Cassin M, De Biasio M, Macor F, Burelli C, Vendrametto F, Driussi M, et al. late coronary thrombosis in paclitaxel-eluting stents. Case reports. J Cardiovasc Med 2007;8:284-288 (Pubitemid 46586667)
66. Chrissoheris MP, Mruthyunjayanna V, Donohue TJ. Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature. Conn Med 2006;70:485-90. (Pubitemid 44409605)
67. Helft G, Elalamy I, Laudy C, Tran D, Beygui F, Le Feuvre C, et al. [Clopidogrel and thrombopenia. A case report] [French]. Ann Cardiol Angeiol 2003;52:191-193
68. Jimenez-Quevedo P, Angiolillo DJ, Bernardo E, Sabate M. Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance? Catheter Cardiovasc Interv 2004;62:39-42.
69. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Combination antiplatelet therapy following brachytherapy with restenting: 'It ain't over 'til the fat lady sings'. J Invasive Cardiol 2002;14:115-117
70. Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 2003;60:505-508 (Pubitemid 37466760)
71. Naber CK, Kaiser CA, Rahman YA, Haude M, Erbel R, Baumgart D. [Late thrombosis after intracoronary irradiation and de-novo stent implantation - case report and review of the literature] [German]. Z Kardiol 2001;90:138-143
72. Puri A, Dwivedi SK, Puri VK, Sethi R, Jain A. Very late angiographic stent thrombosis with Cypher stent despite being on aspirin therapy. Indian Heart J 2006;58:61-64 (Pubitemid 44033488)
73. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract 2006;60:863-866 (Pubitemid 43884177)
74. Stabile E, Cheneau E, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med 2004;5:173-176 (Pubitemid 44556561)
75. Tabuchi Y, Nosaka S, Amakata Y, Takamitsu Y, Shibata N. [Perioperative management for nephrectomy in a long-term hemodialysis patient with anticoagulants for coronary stent] [Japanese]. Masui 1998;47:720-725
76. Takeda S, Shirasawa K, Hatakeyama Y, Sasaki Y, Inenaga K, Takeoka R, et al. Late thrombosis of a drug-eluting stent overlapped in the in-stent restenotic lesion of a bare metal stent. Int J Cardiol 2007;116:e25-26. (Pubitemid 46227629)
77. Ten Berg JM, Van Werkum JW, Heestermans A, Jaarsma W, Hautvast RMA, Den Heijer P, et al. Antiplatelet therapy in patients undergoing coronary stenting: the risk of late stent thrombosis. Neth Heart J 2006;14:297-300.
78. van Werkum JW, Heestermans A, Jaarsma W, Hautvast RWM, De Boer MJ, Ten Berg JM. [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel] [Dutch]. Ned Tijdschr Geneeskd 2006;150:863-868
79. Waters RE, Kandzari DE, Phillips HR, Crawford LE, Sketch Jr MH. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. Catheter Cardiovasc Intern 2005;65:520-524
80. Yang J, Wang N, Zhang X, Xu J, Ling F, Zhou L, et al. Late angiographic stent thrombosis in a drug-eluting stent that occurred 20 months after premature discontinuation of clopidogrel administration. Int Heart J 2006;47:707-713 (Pubitemid 44768722)
81. Zimarino M, Renda G, Maddestra N, De Caterina R. Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. Thromb Haemost 2004;92:668-669 (Pubitemid 39248027)
82. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004;62:1187-1189 (Pubitemid 38456516)
83. Zanetti G, Kartalas-Goumas I, Montanari E, Federici AB, Trinchieri A, Rovera F, et al. Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. J Endourol 2001;15:237-311 (Pubitemid 32323325)
84. Alain M, Goldberg LH, Salasche SJ. Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy. Dermatol Surg 2002;28:992-998
85. Scottish Intercollegiate Guidelines Network. Acute coronary syndromes: a national clinical guideline. (SIGN; no. 93). Edinburgh: Scottish Intercollegiate Guidelines Network; 2007.
86. Amman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making.JAMA 2000;284:835-842
87. Caprie SC. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
88. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528-532 (Pubitemid 38174442)
89. Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22(Suppl 4):19-27. (Pubitemid 40066090)
90. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-628 (Pubitemid 35264538)
91. Cannon CP, on behalf of the Caprie Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis. Am J Cardiol 2002;90:760-762
92. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin. Results from CAPRIE. Drug Saf 1999;21:325-335
93. Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006;96:660-664 (Pubitemid 44782547)
94. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, Cadet Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2004;2:1934-1940 (Pubitemid 40192746)
95. Bhatt DL. Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? Nat Clin Pract Cardiovasc Med 2006;3:182-183
96. Massel D. Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction. ACP J Club 2006;144:58-59
97. Adams RJ. Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy? Nat Clin Pract Neurol 2006;2:532-533
98. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
99. Ballew KA. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high-risk atherothrombosis. ACP J Club 2006;145:33.
100. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002;1:273-288
101. BCIS audit returns 2006: copy of a presentation made at Dublin, September 2007, by Peter E Ludman (BCIS National Audit Officer) on behalf of the Council of the British Cardiovascular Intervention Society [online]. British Cardiovascular Intervention Society; 2007. Available from: www.bcis.org.uk/ resources/audit/audit-2006 (accessed 15 May 2007).
102. Collinson J, Flather MD, Fox KA, Findlay I, Rodrigues E, Dooley P, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000;21:1450-1457 (Pubitemid 30636324)
103. Stenestrand U, Lindback J, Wallentin L. Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006;296:1749-1756 (Pubitemid 44547795)
104. Badia X, Bueno H, Gonzalez Juanatey JR, Valentin V, Rubio M. [Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain] [Spanish]. Rev Esp Cardiol 2005;58:1385-1395
105. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med 2004;255:562-570 (Pubitemid 38534869)
106. Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol 2006;109:307-316 (Pubitemid 44275133)
107. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in spain. Value in Health 2004;7:52-60.
108. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-259 (Pubitemid 40216242)
109. Lyseng-Williamson KA, Plosker GL. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006;24:709-726 (Pubitemid 43998823)
110. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-789 (Pubitemid 34041389)
111. Claxton K, Ginnelly L, Sculpher MJ, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess 2004;8(31). (Pubitemid 39172656)
112. Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, et al. A pilot study of value of information analysis to support research recommendations for NICE. CHE Research Paper 4. York: Centre for Health Economics; 2005.
113. Philips Z, Claxton K, Palmer S, Bojke L, Sculpher M. Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary Int J Technol Assess Health Care 2006;22:379-387
114. Philips Z, Claxton K, Palmer S. The half-life of truth? What is the appropriate time horizon for research decisions? Med Decis Making 2008;28:287-99.
115. Shuchman M. Delaying generic competition-corporate payoffs and the future of Plavix. N Engl J Med 2006;355:1297-1300 (Pubitemid 44465456)
116. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51:149-162 (Pubitemid 30138050)
117. Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ 2004;5:175-182 (Pubitemid 38832960)
118. Frank R, Salkever D. Generic entry and the pricing of pharmaceuticals. J Econ Management Strategy 1997;6:75-90.
119. Koh T. Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. Eur Heart J 2004;25(Suppl):1364 (Pubitemid 38998512)
120. Pascual Figal DA, Valdes Chavarri M, Ruiperez JA, Cortes R, Lopez Palop R, Pico Aracil F, et al. [Subacute stent thrombosis in a nonselected population using antiplatelet therapy: frequency and predictors] [Spanish]. Rev Esp Cardiol 2000;53:791-796
121. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medication to Block Platelets Optimally (JUMBO) - TIMI 26 trial. Circulation 2005;111:3366-3373 (Pubitemid 40931949)
122. Diener P-C, Bogousslavsky PJ, Brass PLM, Cimminiello PC, Csiba PL, Kaste PM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337 (Pubitemid 38970009)